acetylleucine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	71	99-15-0

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

acetylleucine
(S)-2-Acetamido-4-methylpentanoic acid
Acetyl-L-leucine
N-Acetylleucine

used for treating vestibular-related imbalance and vertigo

Molecular weight: 173.21
Formula: C8H15NO3
CLOGP: 0.86
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 66.40
ALOGS: -1.20
ROTB: 4

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70	55
kinase-selectivity-class	ACVR2B,AXL,BRAF,CDK4,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,TEK,TGFBR1,ZAP70	16
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate antidiuretic hormone secretion	69.08	55.52	17	494	19488	90608448

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anticoagulation drug level above therapeutic	73.81	58.97	14	429	2576	42618316

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatitis acute	67.32	50.42	18	926	18748	110569607
Haematoma	65.87	50.42	23	921	58453	110529902
Anticoagulation drug level above therapeutic	62.48	50.42	13	931	4617	110583738
Fall	58.54	50.42	45	899	603437	109984918
Inappropriate antidiuretic hormone secretion	52.71	50.42	17	927	33834	110554521

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N07CA04	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS ANTIVERTIGO PREPARATIONS Antivertigo preparations
CHEBI has role	CHEBI:25212	metabolites

Related Drugs by ATC class:

N07CA Antivertigo preparations 3 drugs

betahistine cinnarizine flunarizine

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.9	acidic
pKa2	13.57	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D07350	KEGG_DRUG
2375522	RXNORM
C0256552	UMLSCUI
CHEBI:17786	CHEBI
CHEMBL1875805	ChEMBL_ID
DB13226	DRUGBANK_ID
CHEMBL56021	ChEMBL_ID
70912	PUBCHEM_CID
5209	INN_ID
C088117	MESH_SUPPLEMENTAL_RECORD_UI
K76S41V71X	UNII
DB16956	DRUGBANK_ID
43224	MMSL
d10224	MMSL
4043428	VANDF
005881	NDDF
019864	NDDF
735136009	SNOMEDCT_US

Pharmaceutical products:

None